

Claims

1. A method of inducing the body to produce an antibody against the region of the CCR5 receptor in wild type individuals, that is affected by the delta 32 deletion comprising using a vaccine including a polypeptide having the following sequence :

Inc A'

~~Tyr-Ser-Gln-Tyr-Gln-Phe-Trp-Lys-Asn-Phe-Gln-Thr-Leu-LysIle-V~~
~~al-Ile-Leu-Gly-Leu-V al-Leu-Pro-Leu-Leu-V al-Met-V al-Ile-Cys-~~
~~TyrSer-Gly-Ile-Leu-Lys-Thr-Leu-Leu-Arg-Cys-Arg-Asn-Glu-Lys-~~
~~Lys-Arg.~~

2. The method according to claim 1 wherein the vaccine is a derivative of said polypeptide.

3. The method according to claim 1 wherein said vaccine produces an antibody bound to the CCR5 site.

4. A method of treating a patient infected with HIV comprising using a vaccine including a polypeptide having the following sequence :

Inc A'

~~Tyr-Ser-Gln-Tyr-Gln-Phe-Trp-Lys-Asn-Phe-Gln-Thr-Leu-LysIle-V~~
~~al-Ile-Leu-Gly-Leu-Val-Leu-Pro-Leu-Leu-Val-Met-V al-Ile-Cys-~~
~~TyrSer-Gly-Ile-Leu-Lys-Thr-Leu-Leu-Arg-Cys-Arg-Asn-Glu-Lys-~~

Lys-Arg

wherein said vaccine produces an antibody against the region of the CCR5 receptor in wild type individuals, that is affected by the delta 32 deletion.

5. The method according to claim 2 wherein the vaccine is a derivative of said polypeptide.

6. A vaccine for producing an antibody against the region of the CCR5 receptor in wild type individuals, that is affected by the delta 32 deletion comprising a polypeptide having the following sequence :

Ans a'

~~Tyr-Ser-Gln-Tyr-Gln-Phe-Trp-Lys-Asn-Phe-Gln-Thr-Leu-LysIle-~~
~~Val-Ile-Leu-Gly-Leu-V al-Leu-Pro-Leu-Leu-Val-Met-Val-Ile-Cys-~~
~~TyrSer-Gly-Ile-Leu-Lys-Thr-Leu-Leu-Arg-Cys-Arg-Asn-Glu-Lys-~~
~~Lys-Arg~~

7. A method of vaccination comprising providing a polypeptide that causes a body to generate antibodies in response to said polypeptide, said antibodies inactivating viral receptors.

8. The method according to claim 7 wherein said polypeptide has the following sequence:

Ans a'

~~Tyr-Ser-Gln-Tyr-Gln-Phe-Trp-Lys-Asn-Phe-Gln-Thr-Leu-LysIle-Val-Ile-Leu-~~
~~Gly-Leu-V al-Leu-Pro-Leu-Leu-Val-Met-Val-Ile-Cys-TyrSer-Gly-Ile-Leu-Lys-~~
~~Thr-Leu-Leu-Arg-Cys-Arg-Asn-Glu-Lys-Lys-Arg.~~

9. The method according to claim 8 wherein the vaccine is a derivative of said polypeptide.

10. The method according to claim 9 wherein said vaccine produces an antibody bound to the CCR5 site.

10. The method according to claim 9 wherein said vaccine produces an antibody bound to the CCR5 site.